Neyrokhirurgia-Grinberg-2010-pdf
.pdf30. |
10 |
3 7 13 -
. -
, -
, 24.
30.1.1.2.
, -
, . . 30-3 (NB:
).
. 30-3. , -
* ( 34)
|
|
|
|
|
|
|
|
|
† |
|
70-99% |
NASCET6 |
|
16,5 2 |
|
>60% |
ECST7 |
|
11,6 3 |
|
50-69% |
NASCET35 |
‡ |
10,1 5 |
|
<30% |
NASCET35 |
|
0,8 5 |
|
<40% |
ECST36 |
|
3 |
|
|
|
|
|
|
>60% |
ACAS§ |
|
6,3 5 |
( . .836) |
>50% |
VACS |
|
|
|
<90% |
CASANOVA |
|
|
* : NASCET – North American Symptomatic Carotid Endarterectomy Trial; ECST – European Carotid Surgery Trial; CASANOVA – Carotid Artery Stenosis with Asymptomatic Narrowing; ACAS – Asymptomatic Carotid Atherosclerotic Study; VACS – Veteran’s Administration Cooperative Study; – ; –
† -
‡ (
)
§ ,
,
( . .836)
( . .837)
30. |
11 |
6 (NASCET) , -
( ) 120
(>70%)
( 17% 18 )
( 7% 18 )
» . ,
90-99%, ,
70-79%. NB: -
NASCET ECST . . 30-2, .834.
5,8%
. . 836.
1.(« »): . -
, .842
2.: . -
, .842
3.( ., -
)
-
( ., , -
). , -
, ( . . -
, .842).
, 4-6
. ,
( . ) , -
, -
7 .
[ 37, -
38( .226-30)]:
30. |
12 |
: ,
6 , , (>180/110), -
, : -
,
24 , -, (<7 ),
, ,
( )
:
, , >3
>5 -
, 2 -
, -
( 1.935 )
4
, -
), . . 30-4.
. 30-4. -
38)
|
* |
|
|
( 1.935 - |
|
|
|
|
|
) |
|
I |
|
; |
|
<1% (5 , 6 |
|
|
|
) |
|
||
|
; - |
|
|
||
|
- |
|
|
||
|
|
|
|
|
|
II |
|
; |
|
1,8% (6 , 7 |
|
|
, |
) |
|
||
|
|
|
|
||
|
- |
|
|
||
|
) |
|
|
|
|
III |
; - |
4% [9 - |
|||
|
; |
|
, |
10 |
|
|
|
, 10 (1 |
|||
|
|
|
|
)] |
|
|
30. |
13 |
|
|
|
|
|
IV |
; - |
8,5% [27 |
(8 |
|
|
), 14 , 2 |
|
|
|
|
|
|
|
] |
|
* ( , -
) .
(342 )
5 , -
,
.
, . 5
-. .
. -
, IV- -
,
.
( )
1.325 3 2 , 5
39 (NB: ,
, ,
40)
( )
2.(
100 )
3.110-150 . . (
)
A.24 -
, « » -
;
-
30. |
14 |
1.– -
2.-
( )
3.(Neo-Synephrine®) -
C.:
(Nipride®); -
4.24-48
); 24-72
( : , 325 +
75 3
41)
5.:
A.10 -
B.40 40
24 :
( )
:
, :
A.( -
)
B.( -)
C.(
)
2.( , -
)
3.( ) ( -
)
4.( -
)
5.( -
, -
30. |
15 |
;
6-12 , -
, )
6.( -
)
7.:
,
( )
, , -
5% ( -
3%).
1.42:2,3%
2.: , -
( . )
A.:
1.:
2.( ,
)
3.: ,
B.:
1.:
3.: ,
C.( ): -
43. = 0,33%.
.
( -
43-45)
3.( )42: 5%
A.(
):
B.( ):
<0,6% 46. -
47 ( . ). 2
30. |
16 |
, 3-4
. -
-
1., ,
38( .249)
3.-
[
,
.
38( .249-50)]
4.4 -
(
)
5., -
38( .229): 0,8%, -
33% , –20%
6.:
– 4%, . 2-
5%38( .249)
4.: .
.
1% 38( .229)
5.48: -
, ( 5- 13 ), 0,4%46 1%49. -
46, 50 .
, -
( . .264)
6.: 25%
1 . ½ >
50%51. 2 -
, 2 52
30. |
17 |
7.( .
): -
-
-
. -
, -
53 (± -
,
Halothane®,
46). 54.
-
8.: -
, -
9.:
A.-
: 1% ( XII -
). -
, .
-
55.
,
. 4
B.-
: 1%
C.-
10. 46
11. 56,57: 5-7 . -
A. , -
( ),
( ,
)
30. |
18 |
B.,
;
( ,
)38
A.( ., ) -
-
58 ( , -
45 ,
). -
. -
38( .255):
1.3 ( , )
2.,
( )
3.,
. -
,
#4, ( -
)
4.,
B.(
):
1.( ., Plasmanate®) -
2.( ., ) -
180 . .
4.( )
C.-
:
1.: , -
, , .
2.:
. ( ., -
),
30. |
19 |
3., :
A.– ,
( ). -
,
. (
) -
,
,
B.– ,
(
). , -
( ., ),
-
C., -
-
38( .191-204)
( )
. -
, ., -
. 1-4% .
1.: « -
» 59,60.
: ( -
-
), .
.
61
2., ( -
125-250 -
15-30 ,
39)
A.